AtriCure (ATRC) Misses Q4 EPS by 13c, provides guidance

AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.33), $0.13 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $124.28 million versus the consensus estimate of $120.37 million.

GUIDANCE:

AtriCure sees FY2025 EPS of ($0.64)-($0.57), versus the consensus of ($0.60). AtriCure sees FY2025 revenue of $517-527 million, versus the consensus of $522.6 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Netcapital gets second Nasdaq notice over late financial filings
• ShinyHunters hackers say they stole psychiatric and medical records of DBI staff - Reuters